NA

Naturalendo Tech Co., Ltd

Biotech R&D of natural ingredients for health and wellness solutions.

168330 | KO

Overview

Corporate Details

ISIN(s):
KR7168330009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 255 번길 58, 에이동 301호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Naturalendo Tech Co., Ltd. is a biotechnology company specializing in biosciences, herbs, and endocrinology. The company engages in the research, development, manufacturing, and sale of hormone biotechnology products, biological agents, and food additives. It focuses on developing health and beauty solutions derived from natural ingredients. The company's core activities revolve around the R&D and commercialization of new functional materials for the health and wellness sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.1 KB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.4 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.9 KB
2025-03-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.6 KB
2025-03-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.4 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.4 KB
2025-03-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.9 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Naturalendo Tech Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Naturalendo Tech Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Naturalendo Tech Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.